Investigators assessed the factors associated with medication treatment for opioid use disorder and whether it is linked to hepatic decompensation or death in patients with cirrhosis and active opioid use disorder.
The natural history of cirrhosis is significantly affected by the increasing prevalence of infections, with strategies for prevention and treatment difficult to compose.
Researchers summarized the reciprocal interaction between sleep and liver diseases, including cirrhosis, and investigated potential approaches for therapeutic interventions.
Researchers studied the impact of current opioid agonist therapy on initiation of chronic hepatitis C virus treatment among a population of individuals who inject drugs.
Investigators conducted an ongoing prospective cohort study to better understand the safety and efficacy of nucleoside and/or nucleotide analogs among patients with hepatitis B virus-related acute-on-chronic liver failure.
Investigators estimated the incidence of HBsAg seroclearance in patients with hepatitis B virus infection on long-term therapy with entecavir or tenofovir disoproxil fumarate.
Findings emphasize the importance of strategies to help HBV-HIV coinfected patients maximize antiretroviral adherence to achieve hepatitis B viral suppression.
Vaxelis is the first hexavalent combination vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Researchers aimed to characterize serological, virological, and histological profiles during and after multidose ARC-520 treatment in patients with chronic HBV.
Researchers assessed the influence of direct-acting antivirals on gut microbiota by analyzing microbial diversity and composition in patients with hepatitis C virus infection with or without HIV.
Studies have demonstrated an association between direct-acting antiviral therapy and a reduction in both the incidence and severity of extrahepatic manifestations of HCV.
